Zealand Pharma Informs of Commercial and Regulatory Status Updates Provided by Sanofi (France) on Lyxumia® for Type 2 Diabetes
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs that Sanofi (SANF.PA) today provided an update on the status for Lyxumia® and the Lantus®/Lyxumia® combination product. Lyxumia® (lixisenatide), the first once-daily prandial GLP-1 agonist for the treatment of adults with Type 2 diabetes, is a Zealand discovered peptide drug. Worldwide rights to develop and sell lixisenatide are exclusively licensed to Sanofi, covering also its use in combination treatments, including combinations with Lantus®, Sanofi’s leading diabetes product and the world’s most prescribed basal insulin product.
Help employers find you! Check out all the jobs and post your resume.
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs that Sanofi (SANF.PA) today provided an update on the status for Lyxumia® and the Lantus®/Lyxumia® combination product. Lyxumia® (lixisenatide), the first once-daily prandial GLP-1 agonist for the treatment of adults with Type 2 diabetes, is a Zealand discovered peptide drug. Worldwide rights to develop and sell lixisenatide are exclusively licensed to Sanofi, covering also its use in combination treatments, including combinations with Lantus®, Sanofi’s leading diabetes product and the world’s most prescribed basal insulin product.
Help employers find you! Check out all the jobs and post your resume.